aap Implantate AG / Change in the Supervisory Board at aap Implantate AG
. Processed and transmitted by Nasdaq Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
aap Implantate AG ("aap") announces that Ronald Meersschaert will resign
from his office as a member of the Supervisory Board for personal
reasons. His duties will conclude on 5 October 2016. Ronald Meersschaert
was first elected as a member of aap's Supervisory Board by the annual
general meeting in financial year 2009. His successor will be Ms.
Jacqueline Rijsdijk (60), who was elected as a substitute member for Mr.
Meersschaert. Jacqueline Rijsdijk is a Board Advisor in the Netherlands
and member of several Supervisory Boards and control committees of
reputable companies such as Deloitte Netherlands and Royal Cosun.
Biense Visser, Chairman of the Supervisory Board at
aap
, praises the work of Ronald Meersschaert over the past years: "We thank
Ronald Meersschaert for his great commitment and the outstanding work
for
aap
on the way to a focused trauma company in recent years. As a recognised
financial expert and seasoned investor, he was always a competent and
trusted contact for the Supervisory and Management Boards and made a
significant contribution in both financial and strategic matters."
In addition Biense Visser welcomes Jacqueline Rijsdijk's acceptance of
the Supervisory Board mandate: "Jacqueline Rijsdijk is a regarded Board
Advisor with comprehensive economic and financial knowledge and an
excellent network. We are very much looking forward to our cooperation
and are sure that
aap
will benefit from her distinctive financial expertise and many years of
experience."
About aap Implantate AG
aap Implantate AG is a globally operating medical device company
headquartered in Berlin, Germany. The company develops, manufactures and
markets trauma and biomaterials products for orthopedics. The trauma
portfolio includes besides the innovative anatomical plating system
LOQTEQ(R) a wide range of cannulated screws as well as standard plates
and screws. In the biomaterials business the company is specialized on
bone cements and mixing systems. In German-speaking countries aap
Implantate AG directly sells its trauma products to hospitals, buying
syndicates and hospital groups while it uses a broad network of
distributors in more than 60 countries at the international level. In
the biomaterials business sales are handled via OEM and private label
cooperations with several selected international orthopedic and trauma
companies. aap Implantate AG's stock is listed in the Prime Standard
segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more
information, please visit www.aap.de, or download the Company's investor
relations app from the Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and
currently available information. They are not guarantees of future
performance. Various known and unknown risks, uncertainties and other
factors could lead to material differences between the actual future
results, financial situation, development or performance of the company
and the estimates given here. Many factors could cause the actual
results, performance or achievements of aap to be materially different
from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does
not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or
developments.
For inquiries please contact: aap Implantate AG, Fabian Franke, Investor
Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: aap Implantate AG via Globenewswire
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
WKN: 506660;ISIN: DE0005066609;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
http://www.aap.de
(END) Dow Jones Newswires
September 12, 2016 06:02 ET (10:02 GMT)
